Registry for haemophiliacs in France : FranceCoag Network. Thierry Lambert, MD

Similar documents
Haemophilia Registries quantity versus quality

EUHASS (European Haemophilia Safety Surveillance) Mike Makris Sheffield, UK

Common Inherited Bleeding Disorders

Clinical Policy: Humate-P (Antihemophiliac Factor/von Willebrand Factor Complex Human) Reference Number: CP.MP.404

DOWNLOAD : STATISTICS OF HEMOPHILIA

Factor Concentrates. More is better? Alexander Duncan MD Emory Medical Labs

Common Inherited Coagulation Disorders. Inherited Coagulation Disorders. All coagulation factors and platelets in circulation (unactivated)

First Name Last Name Patient Gender. Patient DOB Patient Phone # Alternative Phone # City State Zip code. Prescriber Name Contact Name Contact Phone #

Regulatory challenges and opportunities for the use of Real World Evidence for drug registration and labelling

Launches The Many Faces of Bleeding Disorders educational video podcast together with the World Federation of Hemophilia

CLOTTING FACTOR REPLACEMENT THERAPY

The Coagulation Workup In The Office Setting

Prior Authorization Criteria Hemophilia/Blood Factor Products

Abdulkareem Almomen, MD, FRCPC, Professor of Medicine-Hematology, King Saud University & Blood and Cancer Center, Riyadh Jeddah, 24 February 2018

LABORATORY APPROACH TO BLEEDING DISORDERS DR NISHANTH PG 1 ST YEAR DEPARTMENT OF PATHOLOGY

The Role of Disease Foundations in Moving Gene Transfer Forward

Insight HEMOPHILIA. Drug Class. Injury Occurs. Background, new developments, key strategies INTRODUCTION. 20,000 patients in the US 1 MISSING LINK

General Principles of. Hemostasis. Kristine Krafts, M.D.

Hemophilia and inhibitors

Andrew Schorr: Is there anything you ve been discussing that you d like to update people about now?

70% not diagnosed, 75% not treated Many die in childhood or grow-up severely disabled

Annex II. Scientific conclusions

See Important Reminder at the end of this policy for important regulatory and legal information.

Hemophilia A and B Recombinant Factor Replacement Therapy - 5EU Drug Forecast and Market Analysis to 2024

Hemophilia A and B Recombinant Factor Replacement Therapy - 5EU Drug Forecast and Market Analysis to 2024

AUSTRALIAN BLEEDING DISORDERS REGISTRY

Title of Manual: Specimen Collection Document Number: GPA.SPC.48.0

Riastap (fibrinogen concentrate, human) Public Summary of Risk Management Plan (Extract from the EU Risk Management Plan Version 3.

European Haemophilia Safety Surveillance System (EUHASS) Mike Makris Sheffield, UK

Clotting Disorder Therapy

Hemophilia A and B Recombinant Factor Replacement Therapy - Argentina Drug Forecast and Market Analysis to 2024

07/30/2013. Record of Revisions IRB Page 1 of 17

Disclosure. Hemophilia: The Royal Treatment. Objectives. Background. History of Hemophilia. Epidemiology 1/4/2018

Alexander Neumeister 2/19/16

Factor VIII Concentrate Factor IX Complex (Coagulation Factors, II, VII, IX, X) Concentrate

Evaluation of Complex Coagulation Cases: Case-Based Illustrations of Important Issues

REQUEST FOR HEMOPHILIA B (FACTOR IX DEFICIENCY)

Laboratory investigation in the Bleeding Patient. Dr Craig Taylor Consultant Haematologist May 2016

A. National Hemophilia Organization

CASE STUDY: The Business Case for Haemophilia Product Traceability

Patients Perspective in Plasma Products (Focus on Hemophilia)

Patients Perspective in Plasma Products (Focus on Hemophilia)

What We Know 3/27/2014. Hemophilia Federation of America Symposium Inhibitor Track. Developed by Sue Geraghty, R.N. 1

Clinical Policy: Factor VIII (Human, Recombinant) Reference Number: CP.PHAR.215 Effective Date: 05/16 Last Review Date: 05/17

THE NEW ZEALAND MEDICAL JOURNAL

Haemophilia care in Europe: a survey of 19 countries

Together, all nine participants have reduced infusions of factor IX concentrates by 99 percent over cumulative 1,650 days

4/5/2017. Molecular Testing Applications in Coagulation. Disclosures. Objectives. Human Genome Chromosome Analysis.

The Patient Reported Outcomes, Burdens, and Experiences (PROBE) Study Phase 1 Methodology and Feasibility

Plasma Testing in the Clinical Coagulation Laboratory: New drugs, new problems.

FREQUENTLY ASKED QUESTIONS

A Review of Coagulation Factor Disorders

LABORATORY APPROCH TO THE BLEEDING PATIENT

Haemostasis. The function of haemostasis is: to prevent blood loss from injured vessels. to stop bleeding. to prevent thrombosis

Category Storage Shelf Life Additional Criteria

WFH: Closing the global gap achieving optimal care

Local vasoconstriction. is due to local spasm of the smooth muscle (symp. reflex) can be maintained by platelet vasoconstrictors

Coagulation. Coagulation Limited CGL, CGDF Surveys & Anatomic Pathology Education Programs. Coagulation 117

Molecular diagnosis of haemophilia and other bleeding disorders

Guideline on core SmPC for human plasma derived and recombinant coagulation factor VIII products

Current and Emerging Treatment Paradigms in the Management of Hemophilia

SUBJECT: Public Meeting on Expansion of the Clinical Trial Registry and Results Data Bank [Docket No. NIH ]

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

SALSA MLPA probemix P207-C3 F9 Lot C As compared to version C three reference probes have been removed.

Blood 101. Dr. Karen L. Dallas. Medical Director, Hematopathology & Transfusion Medicine Providence Health Care

Genetics/Genomics in Public Health. Role of Clinical and Biochemical Geneticists in Public Health

LYSARC, ACADEMIC PARTNER OF LYMPHOMA CLINICAL RESEARCH. EN

HUMAN GENETICS INITIATIVE

Laboratory Aspects of recombinant porcine FVIII and extended half life concentrates

Фармакоэкономика. теория и практика. Pharmacoeconomics. theory and practice

Hemophilia Care. Will there always be new people in the world with. Will hemophilia be treated more effectively and safely

RE: Comparative Clinical Effectiveness Research Comments on S from the 110 th Congress

Princess Alexandra Hospital Emergency Department. Clinical Procedure. 1 Introduction

uniqure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients with Severe Hemophilia B

The diffusion of recombinant Factor VIII: a study of physicians preference

SUSTAINABILITY REPORT 2017

Thriving Amid The Turbulent Ride

LYSARC, ACADEMIC PARTNER OF LYMPHOMA CLINICAL RESEARCH. EN

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

Conflict of Interest Disclosures Blood Advances

The World Health Assembly Resolution on availability, safety and quality of blood products (WHA 63.12) Adopted May 2010

Laboratory Monitoring of Anticoagulation

Plasma derived medicines - the evidence for their necessity

Management of Hemophilia under Limited Resources

Jump Starting My Research Career. Shannon L. Meeks, MD March 7, 2018

Introduction. Hemophilia B The Blood CME Center recently launched an Conclusion

UNCLASSIFIED AD DEFENSE DOCUMENTATION CENTER FOR SCIENTIFIC AND TECHNICAL INFORMATION CAMERON STATION, ALEXANDRIA. VIRGINIA UNCLASSIFIED

Hemophilia and Gene Therapy

Blood Product Utilization

Secure national supply - the Australian experience

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON THE CLINICAL INVESTIGATION OF RECOMBINANT FACTOR VIII AND IX PRODUCTS

Recombinant Factor VII vs Cryoprecipitate. Dr. M. Truter Moderator: Prof. Pretorius

Key Issues Dialogue: Hemophilia Featuring thought leaders in the hemophilia community. Biotherapies for Life

Overall progress in the first quarter of 2007

Pearls and Pitfalls in Factor Inhibitor Testing

DEPARTMENT OF CLINICAL LABORATORY SCIENCES SCHOOL OF HEALTH TECHNOLOGY AND MANAGEMENT THE UNIVERSITY AT STONY BROOK STONY BROOK, NEW YORK

CLOTTING FACTORS, COAGULANT BLOOD PRODUCTS & OTHER HEMOSTATICS

Current laboratory practices in the diagnosis and management of haemophilia

Antihemophilic Factor (Recombinant BDD) Fc Fusion Protein (Eloctate): Treatment Cost Comparison and Budget Impact Analysis

University of Groningen. Haemophilia care in Europe O'Mahony, B.; Noone, D.; Giangrande, P.L.F.; Prihodova, L. Published in: Haemophilia

Transcription:

Registry for haemophiliacs in France : FranceCoag Network Thierry Lambert, MD Haemophilia Treatment Center,, Bicêtre

History Before 1994: nothing 1994: set up of "Suivi" thérapeutique National des Hémophiles" " (SNH) National prospective multicenter cohort study Anonymous Limited to haemophilia A or B patients Mains objectives : Pharmacovigilance of clotting factor concentrates for haemophiliacs, inhibitor s s research projects. Yearly or visits (definited( calendar), specific blood sampling for lab tests, plasma, serum and cells preservation. Intermediate quarterly visits for PUP'S. Patients or parents signature Supported by French health authorities and coordinated by Inserm (research organism) 100% monitoring of data

Assessment of SNH (Y2000) (1) T Calvez et al, Haemophilia, 2001

Assessment of SNH (Y2000) (2) "Only" 1240 patients enrolled (estimated population: > 4000) Unequal representation of regions Difficulty to proper follow-up Tough data collection and paperwork No use of frozen samples Increasing cost of blood sample processing Other congenital coagulation proteins defects? Need to evolve

Birth of FranceCoag Network Initiated 28 Jan 2003 Two main objectives : 1. Exhaustive knowledge of haemophiliac's population in France (namely: geographic breakdown, associated pathologies, clotting factor concentrates consumption, healthcare system requirements ) and follow-up of patients with congenital bleeding disorders due to clotting factor deficiency 2. Tool for sanitary surveillance of these patients receiving clotting factor concentrates. Research objectives (notably Pups Protocol)

National, prospective multicenter cohort study. Observational study: no specific scheduled visits or blood sampling. No signed consent. Anonymous. Alleviated data collection Optional signed informed consent for serum, plasma and cell preservation every 3 years. Every severe congenital deficiency of clotting factor may be included (except moderate and mild form for haemophilia) Opens a specific cohort for pup's haemophiliacs. Alleviated data monitoring More patients for the same cost Supported by French health authorities and initially coordinated by Inserm,, now by National Institute for Public Health Surveillance (InVS)

Organization Steering committee: InVS members (coordinating( center) Authorities of health representative Head of Regional Treatment Centres physicians COMETH physicians INSERM delegate Agency of sanitary safety representative Haemophilia patient's association representatives Scientific experts Several missions : Propose and decide on evolutions of the project, animate the Network, estimate the research projects, etc. 5 meetings a year Report of each steering committee meeting sent to all participant physicians.

Scientific Aspects Any physician can submit a research project to the steering committee, using data and eventually biological samples of the FranceCoag cohort Project is reviewed by steering committee and other experts if necessary, prior to acceptation 3 international publications at now 3 running studies

Rythm of inclusions and follow-up 3300 update to nov.. 2004 3000 2700 Inclusions ou followed 2400 2100 1800 1500 1200 900 600 Patients included Followed patients 300 0 0 2 4 6 8 10 12 14 16 18 20 22 Time since the starting of project (months)

Inclusions and follow-up up, per year 15 dec 2004 update Evolution of inclusions and follow-up visits 2003 2004 Total Inclusions Hemophilia * Von Willebrand disease Others 2013 157 69 587 82 28 2600 (89 %) 239 (8 %) 97 (3 %) Total 2239 697 2936 Follow-up Hemophilia Von Willebrand disease Others 86 0 1 936 48 30 1022 (93 %) 48 (4 %) 31 (3 %) Total 87 1014 1101

Repartition by pathologies Maladie Nombre de patients inclus (n) (%) Afibrinogénémie 15 0.5 Déficit en Facteur II 0 - Déficit en Facteur V 11 0.4 Déficit en Facteur VII 27 0.9 Déficit en Facteur VIII 2150 73.2 Déficit en Facteur IX 450 15.3 Déficit en Facteur X 6 0.2 Déficit en Facteur XI 24 0.8 Déficit en Facteur XIII 14 0.5 Déficit en Facteur Willebrand 239 8.1 Total Inclusions 2936 100.0

Assessment Good participation of French HTC's (36 centres participating, 90 physicians) Adhesion of patients 194 Pup's included in Pups Protocol Useful tool of communication and information for haemophiliac's physicians Data collection is moving to electronic means We have faith in development of new research projects issued from this registry

How to know more about FranceCoag Network? Visit Web Site : http://www.francecoag.org www.francecoag.org/